Opinion: My Biggest GLP-1 Ethical Problem: Patients Who Don’t Want to Stop

Why It Matters

The shift impacts prescribing standards, patient health, and regulatory oversight, making it a critical issue for the pharmaceutical and obesity‑treatment markets.

Key Takeaways

• GLP‑1 shortages shifted to surplus, creating new ethical issues
• Physicians now face patients wanting unsustainable weight loss
• Off‑label GLP‑1 use for weight persists despite supply changes
• Overuse may trigger eating disorders and health complications
• Balancing access and safety challenges clinicians and regulators

Pulse Analysis

The rapid commercialization of glucagon‑like peptide‑1 (GLP‑1) receptor agonists has transformed both diabetes care and the burgeoning obesity market. After a 2022‑2023 supply crunch that left many patients waiting weeks for prescriptions, manufacturers expanded production and secured distribution channels, resulting in an unexpected surplus by early 2026. This turnaround has lowered prices and broadened insurance coverage, encouraging a wave of new prescriptions for weight‑loss indications. However, the abundance also amplifies off‑label use, prompting clinicians to confront a landscape where the drug is no longer a scarce resource but a readily available tool.

Clinicians now report a growing cohort of individuals who refuse to taper or stop GLP‑1 therapy despite reaching body‑mass indexes that fall below medically recommended thresholds. The drive for rapid, dramatic weight loss can mask underlying eating‑disorder pathology, and prolonged pharmacologic suppression of appetite may exacerbate nutritional deficiencies. Physicians must balance the therapeutic benefits—improved glycemic control, cardiovascular risk reduction, and sustained weight loss—against the risk of fostering unhealthy body image expectations. This ethical tension is heightened by limited guidance on safe discontinuation protocols and the lack of long‑term outcome data.

Regulators and professional societies are responding by drafting clearer prescribing criteria and monitoring frameworks that address both overuse and underuse. Incorporating multidisciplinary assessments, including mental‑health screening, could help identify patients at risk before therapy escalation. For pharmaceutical companies, the challenge lies in aligning commercial incentives with responsible stewardship, perhaps through patient‑education programs and tiered dosing strategies. As the market matures, a data‑driven approach to dosage tapering and post‑treatment follow‑up will be essential to safeguard patient health while preserving the therapeutic promise of GLP‑1 agents.